How to Get Vyvanse in Delaware

Who Can Prescribe Vyvanse in Delaware

Any Delaware-licensed prescriber with an active DEA registration that includes Schedule II authority can write a Vyvanse prescription. This includes physicians (MD/DO), Advanced Practice Registered Nurses (APRNs), and Physician Assistants (PAs).

Delaware removed its collaborative-agreement requirement for APRNs in 2021 under Title 24, Chapter 19 of the Delaware Code. APRNs with full practice authority and a DEA number may independently prescribe Schedule II substances, including lisdexamfetamine. PAs retain a collaborative agreement requirement but can still prescribe controlled substances when their agreement explicitly permits it.

For ADHD specifically, psychiatrists, neurologists, and primary care physicians all commonly initiate Vyvanse. Pediatricians handle most childhood ADHD prescriptions. The prescriber must document a clinical evaluation consistent with DSM-5 criteria before writing the prescription. A single office visit or telehealth encounter is typically sufficient for established patients transferring care, though new diagnoses generally require a more thorough assessment including developmental history and symptom rating scales.

Telehealth Access to Vyvanse in Delaware

Delaware permits telehealth prescribing of Schedule II stimulants, making remote ADHD care a viable pathway for residents statewide.

The DEA's post-pandemic telemedicine rule (finalized in 2025) requires an initial audio-video encounter for new Schedule II prescriptions. Delaware's Board of Medical Licensure aligns with this standard. Once the initial telehealth visit establishes the prescriber-patient relationship, follow-up encounters can use audio-only communication for refills and dose adjustments.

Several national telehealth platforms serve Delaware for ADHD evaluation. Wait times for an initial appointment range from 3 to 14 days depending on the provider. The appointment itself typically lasts 45 to 60 minutes for new evaluations and 15 to 20 minutes for follow-ups. After the visit, the prescriber sends an electronic prescription directly to the patient's pharmacy of choice. Delaware law permits e-prescribing of Schedule II substances, and most major pharmacies accept EPCS (Electronic Prescribing for Controlled Substances).

Patients in rural Sussex County benefit most from telehealth access, as the county has fewer than half the psychiatrists per capita compared to New Castle County. Drive times to a psychiatrist in southern Delaware can exceed 45 minutes each way, making virtual visits a practical alternative.

Delaware Medicaid Coverage and Prior Authorization

Delaware Medicaid (managed through Highmark Delaware and AmeriHealth Caritas) covers Vyvanse for both ADHD and binge eating disorder, but requires prior authorization before dispensing.

The PA process verifies three things: a documented DSM-5 diagnosis, trial-and-failure of at least one first-line agent (typically methylphenidate or generic amphetamine mixed salts), and prescriber attestation that the patient meets clinical criteria. For binge eating disorder, the PA also requires documentation that the patient is 18 or older and has moderate-to-severe symptoms per DSM-5 frequency thresholds.

Turnaround time for Delaware Medicaid PA decisions is 24 hours for urgent requests and up to 72 hours for standard requests. Denials can be appealed within 60 days. The prescriber's office typically initiates the PA, though patients can request a copy of the determination letter.

According to the Wigal et al. study in the Journal of Attention Disorders (2017), lisdexamfetamine demonstrated a mean effect size of 1.52 on ADHD-RS-IV total scores across pediatric trials, supporting its classification as a first-line treatment option after generic stimulant trials. This evidence base is what drives coverage despite the step-therapy requirement.

Commercial insurance plans in Delaware (Aetna, Cigna, UnitedHealthcare, Highmark BCBS) vary in their requirements. Some require only a diagnosis code; others mandate step therapy through generic amphetamine salts first. The arrival of generic lisdexamfetamine in August 2023 has improved formulary positioning on many plans, with copays dropping from $50-$80 for brand to $15-$40 for generic on preferred tiers.

Required Labs and Pre-Prescription Workup

No specific laboratory tests are FDA-mandated before starting Vyvanse. Clinical guidelines recommend a baseline assessment that is primarily physical rather than laboratory-based.

The standard pre-prescribing workup includes: resting heart rate and blood pressure (stimulants raise both by an average of 2-4 bpm and 1-3 mmHg respectively), height and weight (for growth monitoring in pediatric patients), and a cardiovascular history screen. The American Academy of Pediatrics guidelines do not require routine ECG before stimulant initiation unless the patient has a personal or family history of cardiac disease, syncope, or sudden death.

Some prescribers in Delaware order a baseline CBC and metabolic panel, though this is practice-pattern variation rather than guideline-driven necessity. For adult patients with binge eating disorder, prescribers may check a metabolic panel given the association between BED and metabolic syndrome.

The key takeaway: do not delay your appointment waiting for labs. Most clinicians perform the assessment during the initial visit and can prescribe the same day if criteria are met.

Pharmacy Options in Delaware

Vyvanse and generic lisdexamfetamine are stocked at all major retail pharmacies in Delaware, including CVS, Walgreens, Rite Aid, and Walmart locations across all three counties.

Schedule II medications cannot be called in by phone, but Delaware permits electronic prescribing. Your prescriber sends the script digitally, and the pharmacy typically fills it within 2 to 4 hours if the medication is in stock. Supply chain shortages affected stimulant availability in 2023 and early 2024, but production quotas increased by the DEA have largely resolved spot shortages for lisdexamfetamine specifically.

Delaware-licensed 503A compounding pharmacies can prepare lisdexamfetamine in alternative formulations (such as liquid suspensions for patients who cannot swallow capsules) when a prescriber writes a patient-specific prescription. This is distinct from the commercially available chewable tablet (Vyvanse chewable, available in 10 mg through 60 mg strengths). Compounded preparations require the same Schedule II prescription and cannot be refilled.

For cost optimization, patients should check both brand Vyvanse and generic lisdexamfetamine pricing. GoodRx and similar discount platforms show generic lisdexamfetamine at $30 to $80 for a 30-day supply at Delaware pharmacies, compared to $350+ for brand-name Vyvanse without insurance. Takeda's Vyvanse savings program may reduce brand copays to as low as $30 for commercially insured patients, though it excludes government insurance beneficiaries.

Transferring a Vyvanse Prescription to Delaware

Patients relocating to Delaware or visiting from another state face specific rules for Schedule II transfers. Federal law prohibits transferring Schedule II prescriptions between pharmacies. The original prescription must be filled at the pharmacy where it was sent.

If you move to Delaware with remaining refills (note: Schedule II drugs do not have "refills" in the traditional sense, but rather sequential prescriptions), your new Delaware prescriber must write a new prescription. Your previous prescriber can send records to support continuity of care. Most telehealth and in-person providers in Delaware accept patients transferring from out-of-state prescribers and can issue a new prescription after a brief evaluation visit confirming the existing diagnosis and treatment stability.

For short-term visitors, Delaware pharmacies can fill an out-of-state electronic prescription from a prescriber licensed in another state, provided the prescription is valid and the prescriber has an active DEA number. However, some pharmacies may exercise discretion and decline to fill out-of-state controlled substance prescriptions, particularly if the patient is not local.

Timeline from First Appointment to Medication in Hand

The total elapsed time from scheduling an appointment to picking up Vyvanse at a Delaware pharmacy depends on several variables, but here is a realistic timeline.

For patients with an established ADHD diagnosis transferring care: scheduling takes 3 to 7 days, the appointment itself is 15 to 30 minutes, and pharmacy fill time is 2 to 4 hours. Total: roughly one week.

For new ADHD evaluations: scheduling takes 7 to 21 days (longer for psychiatry, shorter for primary care or telehealth), the evaluation is 45 to 60 minutes, any required prior authorization adds 1 to 3 business days, and pharmacy fill time is 2 to 4 hours. Total: two to four weeks.

If prior authorization is denied and an appeal is filed, add another 10 to 30 days. Peer-to-peer reviews between the prescriber and the insurance company's medical director can sometimes overturn denials within 48 hours and are worth requesting before filing a formal appeal.

Documentation for Prior Authorization

Insurance companies reviewing Vyvanse prior authorization requests in Delaware require a specific set of documents. Having these prepared before submission reduces back-and-forth delays.

Standard documentation includes: the patient's DSM-5 diagnosis with supporting clinical notes, prior medication trials with dates and reasons for discontinuation (inefficacy, side effects, or both), current symptom severity documented via a validated rating scale (ADHD-RS-5, ASRS, or Conners), the prescriber's clinical rationale for lisdexamfetamine specifically (such as need for prodrug abuse-deterrent properties, duration of action requirements, or prior response), and the patient's insurance ID and group number.

For binge eating disorder indications, additional documentation includes: frequency of binge episodes (must meet DSM-5 threshold of at least once weekly for three months), documentation that the patient does not have anorexia nervosa or bulimia nervosa (contraindications), and BMI if relevant to the clinical picture.

The FDA-approved prescribing information for Vyvanse notes that lisdexamfetamine's prodrug mechanism provides a distinct pharmacokinetic profile from immediate-release amphetamine, which can support clinical rationale in PA submissions when the insurer questions why generic mixed amphetamine salts are insufficient.

Generic Lisdexamfetamine Availability in Delaware

The FDA approved generic lisdexamfetamine dimesylate capsules in August 2023 following Takeda's patent expiration. Multiple manufacturers now produce the generic, including Alvogen, Teva, and Sandoz.

Delaware pharmacies carry generic lisdexamfetamine in all available strengths (10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules). The generic is AB-rated to brand Vyvanse, meaning the FDA considers it therapeutically equivalent. Pharmacies will automatically substitute generic unless the prescriber writes "brand medically necessary" or the patient requests brand and pays the price difference.

For Delaware Medicaid patients, generic lisdexamfetamine may have a lower tier placement than brand, potentially reducing or eliminating copay requirements. Check your specific plan's formulary, as this varies between Highmark Delaware First Health and AmeriHealth Caritas Delaware.